Acneiform Eruption Secondary to Deucravacitinib: A Case Series and Review of the Literature

Abstract

Acneiform eruptions have been observed and reported in clinical trials for tyrosine kinase 2 (TYK2) inhibitors. However, data on their occurrence in real-world settings remain limited. This case series describes six patients, who developed acneiform eruptions following the initiation of deucravacitinib for chronic plaque psoriasis. Through this case series, we aim to shed further light into the clinical characteristics and potential risk factors for this side effect. Contrary to clinical trial data, we demonstrate high cessation rates of deucravacitinib following the development of acneiform eruption, due to the significant burden on quality of life. We highlight the need to identify risk factors to improve patient selection and allow adequate counselling or prophylactic treatments for these acneiform eruptions.